Results 101 to 110 of about 684,663 (243)
Advanced Materials Interfaces, EarlyView.Solid‐state nanopores are used to interrogate dendrimer‐peptide conjugates with systematically varied peptide loading. Single‐particle ionic current signatures reveal how ligand density modulates deformability, transport pathways, and electromechanical coupling during translocation.
Chaoming Gu +7 more
wiley +1 more source
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Frontiers in Immunology, 2017 The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the ...
Rachel M. Gibbons Johnson +2 more
doaj +1 more source
PD-L1 Status in Refractory Lymphomas
PLOS ONE, 2016 Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various solid tumors. A remarkable improvement has also been observed in the treatment of patients with refractory/relapsing classical Hodgkin lymphoma (cHL). We investigated PD-L1 status in a variety of treatment resistant lymphomas.
Semir Vranic +8 more
openaire +4 more sources
Pioneering of Antibody-Assisted Structure-Based Drug Discovery for PD-L1
, 2023 The principle of antibody-assisted drug discovery aims to use a diverse panel of single domain antibodies (VHH) to identify rare conformational states and/or novel allosteric sites that could modulate function, which may facilitate the discovery of new ...
Tara Kang-Pettinger (15905717)
core +1 more source
Advanced Materials Technologies, EarlyView.Mesenchymal stem cell derived extracellular vesicles (MSC‐EVs) are a promising therapeutic tool for regenerative medicine. However, the field lacks a reproducible high‐yield production method to answer the quantities needed for clinical translation.
Christophe Wong +7 more
wiley +1 more source
Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
Diagnostics, 2020 Recent data have suggested that PD-1 and PD-L1 are involved in osteosarcoma (OS) pathogenesis; however, their contributions are not well-established. Here, the PD-1/PD-L1 expression was evaluated in (OS) cases.
Kazuhiko Hashimoto +2 more
doaj +1 more source
Binding and inhibition assays of anti-PD-L1 antibody.
, 2022 (A) Specific binding to human PD-L1 by ELISA. The Tecentriq® and human IgG1 was used as positive and negative control respectively. Plant-produced anti-PD-1 antibody was also used to confirm the non-specificity to PD-L1.
Thareeya Phetphoung (14106521) +11 more
core +1 more source
Advanced Science, EarlyView.A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang +19 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Diabetes mellitus‐induced erectile dysfunction (DMED) is a highly prevalent complication among diabetic patients; however, its underlying pathogenic mechanisms remain incompletely understood. Metabolic disorder is a hallmark of diabetes, yet its precise contribution to DMED progression is not well defined.
Wanyang Guo +14 more
wiley +1 more source
Advanced Science, EarlyView.The cellular actors of oxytocin signaling are under intense scrutiny. A brain‐wide anatomical and functional analysis in mice and rats reveals widespread expression of oxytocin receptors in astrocytes. These receptors are functionally active and, in the nucleus accumbens, selectively regulate male social affiliation.
Clémence Denis +32 more
wiley +1 more source